Literature DB >> 20233200

Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.

Guillaume Montastruc1, Sylvie Favreliere, Agnès Sommet, Atul Pathak, Maryse Lapeyre-Mestre, Marie-Christine Perault-Pochat, Jean-Louis Montastruc.   

Abstract

AIMS: To evaluate putative associations between drugs and dilated cardiomyopathy.
METHODS: We used the case/noncase method in the French PharmacoVigilance Database (FPVD). Cases were all the observations with dilated cardiomyopathy registered into the FPVD between 1 January 1990 and 30 June 2007. Noncases were all other reports other than those studied. Anthracyclines were used as positive controls. Data were expressed as reporting odds ratio (ROR) with their 95% confidence intervals.
RESULTS: Out of the 258 729 adverse drug reaction (ADR) reports recorded in the FPVD between 1 January 1990 and 30 June 2007, 47 (22 men, mean age 49 years) were defined as dilated cardiomyopathy. In these 47 patients, 67 drugs were 'suspect'. A significant ROR was found with cytotoxic (epirubicin, mitoxantrone, cyclophosphamide, gemcitabine, fluorouracil) and antiretroviral (lamividune, zidovudine, abacavir) but also with isotretinoin, prednisone, appetite suppressant (clobenzorex) and psychotropic [antipsychotic (clozapine, olanzapine), lithium, antidepressant (clomipramine, amitriptyline, fluvoxamine)] drugs.
CONCLUSIONS: The present study describes an association between some drugs and reports of dilated cardiomyopathies. This relationship involves not only some already suspected drugs (anthracyclines, antiretrovirals), but also other drugs (antipsychotics, lithium, antidepressants, retinoids) less known to induce such an ADR. Despite the mandatory limits of this kind of study (underreporting, confounding factors . . .), these data represent a pharmacovigilance signal and could contribute to establish further prospective studies in order to confirm such signals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233200      PMCID: PMC2829699          DOI: 10.1111/j.1365-2125.2009.03596.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

Review 1.  Mitochondrial studies in HAART-related lipodystrophy: from experimental hypothesis to clinical findings.

Authors:  Oscar Miró; Sónia López; Francesc Cardellach; Jordi Casademont
Journal:  Antivir Ther       Date:  2005

2.  Recurrence of dilated cardiomyopathy after re-introduction of a tricyclic antidepressant.

Authors:  F Briec; C Delaire; J B Bouhour; J N Trochu
Journal:  Arch Mal Coeur Vaiss       Date:  2006-10

3.  Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.

Authors:  W M Stadler; T Kuzel; M Dumas; N J Vogelzang
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

Review 4.  Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003.

Authors:  Steven J Haas; Richard Hill; Henry Krum; Danny Liew; Andrew Tonkin; Lisa Demos; Karen Stephan; John McNeil
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 5.  Drug-induced heart failure.

Authors:  J Feenstra; D E Grobbee; W J Remme; B H Stricker
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

Review 6.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

7.  Cardiomyopathy after long-term treatment with lithium - more than a coincidence?

Authors:  W Aichhorn; R Huber; C Stuppaeck; A B Whitworth
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

Review 8.  Drug-induced cardiovascular disorders.

Authors:  C Aengus Murphy; Henry J Dargie
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

Review 10.  Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

Authors:  Saskia K Klein; Bart J Biemond; Marinus H J van Oers
Journal:  Ann Hematol       Date:  2007-07-10       Impact factor: 3.673

View more
  10 in total

1.  Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.

Authors:  Jean-Louis Montastruc; Agnès Sommet; Haleh Bagheri; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

2.  Reply to: Timothy A C Snow, Cara A Wasywich and Fiona M Stewart. A case of breathlessness during pregnancy: the difficulty in diagnosing heart failure Obstet Med OM.2012.120031; published ahead of print 20 December 2012, doi:10.1258/OM.2012.120031.

Authors:  Adam Morton
Journal:  Obstet Med       Date:  2013-05-03

3.  Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.

Authors:  Jean-Baptiste Bossard; Camille Ponté; Julie Dupouy; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

4.  Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.

Authors:  Francois Chavant; Sylvie Favrelière; Claire Lafay-Chebassier; Caroline Plazanet; Marie-Christine Pérault-Pochat
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

5.  Olanzapine Induced Dilated Cardiomyopathy.

Authors:  Beeresha Puttegowda; Joseph Theodore; Ramesh Basappa; Manjunath Cholenally Nanjappa
Journal:  Malays J Med Sci       Date:  2016-03

Review 6.  Systematic Review of Clozapine Cardiotoxicity.

Authors:  Martina Curto; Nicoletta Girardi; Luana Lionetto; Giuseppino M Ciavarella; Stefano Ferracuti; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-07       Impact factor: 5.285

Review 7.  Gemcitabine-induced cardiomyopathy: a case report and review of the literature.

Authors:  Muhammad F Khan; Silvija Gottesman; Ravichandra Boyella; Elizabeth Juneman
Journal:  J Med Case Rep       Date:  2014-06-23

8.  Gemcitabine-Induced Cardiotoxicity in Patients Receiving Adjuvant Chemotherapy for Pancreatic Cancer: A Case Series.

Authors:  Salma Alam; Chidi Illo; Yuk Ting Ma; Pankaj Punia
Journal:  Case Rep Oncol       Date:  2018-04-05

9.  A novel approach to cardiovascular disturbances in patients with schizophrenia spectrum disorders treated with long-acting injectable medication.

Authors:  Minodora Andor; Liana Dehelean; Ana-Maria Romosan; Valentina Buda; Gabriela Radu; Florina Caruntu; Aurora Bordejevic; Minodora Marinela Manea; Ion Papava; Cristina Ana Bredicean; Radu Stefan Romosan; Mirela Tomescu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-25       Impact factor: 2.570

10.  Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome.

Authors:  LouJin Song; Ramsey Bekdash; Kumi Morikawa; Jose R Quejada; Alison D Klein; Danielle Aina-Badejo; Kazushige Yoshida; Hannah E Yamamoto; Amy Chalan; Risako Yang; Achchhe Patel; Dario Sirabella; Teresa M Lee; Leroy C Joseph; Fuun Kawano; Junco S Warren; Rajesh K Soni; John P Morrow; Masayuki Yazawa
Journal:  Nat Cardiovasc Res       Date:  2022-02-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.